Conventional and Unconventional Wisdom: Emerging Approaches to Oncology Drug Dosing and Implications for Health-System Pharmacy
Featured Speaker: Mark J. Ratain, M.D.
Dr. Ratain has pioneered the field of cancer pharmacogenetics and directs research efforts in phase I cancer clinical trials aimed at determining the clinical pharmacology of new anticancer drugs at the University of Chicago. In this session, he will discuss the data supporting the labeled dosing of oncology agents as compared to alternative approaches. Clinical implications will be explored, including those related to drug-drug- and drug-food interactions.
The following awards will also be presented:
ASHP Research and Education Foundation 2013 Literature Awards
ASHP Research and Education Foundation 2013 Award for Sustained Contributions to the Literature of Pharmacy Practice, presented to Dr. Marie A. Chisholm-Burns, PharmD, MPH, FCCP, FASHP, Dean and Professor, University of Tennessee Health Science Center College of Pharmacy
- Describe the data supporting the conventional use of body surface area based dosing.
- Discuss the state of development of germline pharmacogenetic diagnostics for oncology drugs.
- Name the risks to patients regarding food intake in conjunction with oral oncology drugs.
- Recognize challenges of drug-drug interactions in oncology.